NEW YORK, March 10, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of OPKO Health, Inc. (“OPKO” or the “Company”) (NASDAQ: OPK). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980.
The investigation concerns whether OPKO and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On March 5, 2020, OPKO’s subsidiary BioReference Laboratories issued a press release stating “that it will offer a test for the novel coronavirus (2019-nCoV)” and “is expecting to receive specimens for testing, and begin to provide testing next week. With an extensive network of patient service centers and a national logistic network, BioReference will provide expanded access to a COVID-19 testing across the United States.” Then, on March 9, 2020, Hindenburg Research stated via Twitter that OPKO was “an obvious coronavirus pump,” characterizing the Company’s March 5 press release as “nonsense” and noting that the Company’s Chief Executive Officer Phillip Frost “has been accused by the SEC of engaging in pump and dump schemes in the past.” On this news, OPKO’s stock price fell sharply, damaging investors.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
888-476-6529 ext. 9980